University Medical Center Utrecht-ko ikertzaileekin lankidetzan egindako argitalpenak (40)

2024

  1. Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time?

    Arthritis Care and Research, Vol. 76, Núm. 1, pp. 88-97

2023

  1. Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies

    Rheumatology (United Kingdom), Vol. 62, Núm. 1, pp. 243-255

  2. ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products

    Clinical and experimental rheumatology, Vol. 41, Núm. 3, pp. 543-553

2022

  1. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

  2. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Respiratory Medicine, Vol. 8, Núm. 10, pp. 963-974

2019

  1. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: The European Scleroderma Observational Study

    Rheumatology (United Kingdom), Vol. 57, Núm. 2, pp. 370-381

  2. Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study

    Annals of the Rheumatic Diseases, Vol. 77, Núm. 4, pp. 563-570

2017

  1. An MIF promoter polymorphism is associated with susceptibility to pulmonary arterial hypertension in diffuse cutaneous systemic sclerosis

    Journal of Rheumatology, Vol. 44, Núm. 10, pp. 1453-1457

  2. Treatment outcome in early diffuse cutaneous systemic sclerosis: The European Scleroderma Observational Study (ESOS)

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 7, pp. 1207-1218

  3. Update of EULAR recommendations for the treatment of systemic sclerosis

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 8, pp. 1327-1339

2016

  1. Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies

    Arthritis and Rheumatology, Vol. 68, Núm. 9, pp. 2338-2344

  2. Influence of TYK2 in systemic sclerosis susceptibility: A new locus in the IL-12 pathway

    Annals of the Rheumatic Diseases, Vol. 75, Núm. 8, pp. 1521-1526

2015

  1. Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis

    Clinical and Experimental Rheumatology, Vol. 33, pp. 31-35

2014

  1. A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility

    Arthritis Research and Therapy, Vol. 16, Núm. 1

  2. Identification of IL12RB1 as a Novel Systemic Sclerosis Susceptibility Locus

    Arthritis and Rheumatology

  3. Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis

    American Journal of Human Genetics, Vol. 94, Núm. 1, pp. 47-61

2013

  1. A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci

    Human Molecular Genetics, Vol. 22, Núm. 19, pp. 4021-4029

  2. Confirmation of TNIP1 but not RHOB and PSORS1C1 as systemic sclerosis risk factors in a large independent replication study

    Annals of the Rheumatic Diseases, Vol. 72, Núm. 4, pp. 602-607